S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:IMMX

Immix Biopharma - IMMX Stock Forecast, Price & News

$2.63
+0.03 (+1.15%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.42
$2.71
50-Day Range
$1.05
$2.63
52-Week Range
$0.68
$5.37
Volume
134,726 shs
Average Volume
256,716 shs
Market Capitalization
$36.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Immix Biopharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Immix Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$5,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

804th out of 1,053 stocks

Pharmaceutical Preparations Industry

402nd out of 519 stocks


IMMX stock logo

About Immix Biopharma (NASDAQ:IMMX) Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Stock News Headlines

IMMX Immix Biopharma, Inc.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
IMMX, ZY and SCOR among premarket gainers
Immix Soars on Study Results
See More Headlines
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Company Calendar

Last Earnings
11/09/2022
Today
2/01/2023
Next Earnings (Estimated)
2/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMX
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-24,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.36 per share

Miscellaneous

Free Float
6,782,000
Market Cap
$36.64 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Ilya Rachman M.B.A. (Age 50)
    M.D., MBA, Ph.D., Co-Founder, Chairman & CEO
    Comp: $193.31k
  • Mr. Gabriel Morris B.A. (Age 36)
    CFO & Director
    Comp: $100k
  • Mr. Sean Senn J.D.
    M.B.A., M.Sc., MBA, MSc, Co-Founder
  • Dr. Vladimir P. Torchilin D.Sc. (Age 76)
    MSE, Ph.D., Scientific Co-Founder
  • Mr. Ben H. Lyon J.D.
    Exec. VP & Gen. Counsel
  • Dr. Graham Ross FFPM (Age 63)
    M.D., Acting Chief Medical Officer & Head of Clinical Devel.
  • Mr. Nandan Oza B.S. (Age 61)
    Head of Chemistry, Manufacturing & Control













IMMX Stock - Frequently Asked Questions

Should I buy or sell Immix Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMMX shares.
View IMMX analyst ratings
or view top-rated stocks.

How have IMMX shares performed in 2023?

Immix Biopharma's stock was trading at $2.29 at the beginning of the year. Since then, IMMX shares have increased by 14.8% and is now trading at $2.63.
View the best growth stocks for 2023 here
.

Are investors shorting Immix Biopharma?

Immix Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 172,900 shares, a decrease of 19.2% from the December 31st total of 214,100 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.9% of the shares of the stock are short sold.
View Immix Biopharma's Short Interest
.

When is Immix Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our IMMX earnings forecast
.

How were Immix Biopharma's earnings last quarter?

Immix Biopharma, Inc. (NASDAQ:IMMX) announced its earnings results on Wednesday, November, 9th. The company reported ($0.11) EPS for the quarter.

When did Immix Biopharma IPO?

(IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.

What is Immix Biopharma's stock symbol?

Immix Biopharma trades on the NASDAQ under the ticker symbol "IMMX."

Who are Immix Biopharma's major shareholders?

Immix Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.11%). Insiders that own company stock include Ilya M Rachman and Sean Senn.
View institutional ownership trends
.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immix Biopharma's stock price today?

One share of IMMX stock can currently be purchased for approximately $2.63.

How much money does Immix Biopharma make?

Immix Biopharma (NASDAQ:IMMX) has a market capitalization of $36.64 million.

How can I contact Immix Biopharma?

The official website for the company is www.immixbio.com. The company can be reached via phone at 310-651-8041.

This page (NASDAQ:IMMX) was last updated on 2/2/2023 by MarketBeat.com Staff